knowledge -WSS

knowledge

author：fashion 2025-10-03 00:22:22 - browse：679

Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups.

The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.

First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. Around $25.6 billion had been raised by 556 first-time funds in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： FDA approves first treatment for ultra

explore

WSS

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Beware the threat of staffing cuts at the CDC

Beware the threat of staffing cuts at the CDC

PBM reforms clear House panel

Cancer drug shortages' outsize impact on ovarian cancer patients

ProMED sees offers of support, but its future remains unclear

leisure time

knowledge

hotspot

Activists slam private health insurers over coverage restrictions

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Continuity nursing helped my family in our darkest PICU moments

Trump's false claims about Georgia's 2020 election long debunked

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Bright Health sells Medicare Advantage business to Molina

As Maui death toll rises, number of missing remains unclear

At least 13 dead in Texas as scorching temps continue

Does good food count as health care? Study aims to find out

hotspot

Hilary expected to bring catastrophic, life

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

ProMED sees offers of support, but its future remains unclear

In key trial, Verve's treatment lowers cholesterol levels in patients

A daunting task: navigating dual Medicare, Medicaid eligibility

Clinical trials must include more disabled people

leisure time

knowledge

explore

entertainment